Home
HomeChat
Markets
AlertsCalendarScreenerCharts
Portfolio
WatchlistsPortfolioFiles
Account
Docs
Sign upJoinLog inLogin

Alector, Inc. (ALEC) stock profile

Alector, Inc. is a clinical-stage biopharmaceutical company that develops therapies for the treatment of neurodegenerative diseases. Its product candidates include AL001, a humanized recombinant monoclonal antibody in Phase III clinical trials for frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis, and AL101, which is in Phase I clinical trials for neurodegenerative diseases, including Alzheimer's and Parkinson's. The company also offers AL002, a product candidate in Phase II clinical trials for Alzheimer's disease, and AL003, which is in Phase I clinical trials for Alzheimer's disease. Its pipeline includes AL044, which targets MS4A4A, a risk gene for Alzheimer's disease. Alector has a collaboration agreement with Adimab, LLC for antibody research and development, as well as a strategic collaboration with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

Key facts

SymbolALEC
ExchangeNASDAQ
SectorHealthcare
IndustryBiotechnology
CEOArnon Rosenthal
Employees175
HeadquartersSouth San Francisco, CA, US
IPO2019-02-07
Websitewww.alector.com

Explore ALEC on Vantafin

  • Alector, Inc. Overview
  • Alector, Inc. Financials
  • Alector, Inc. News
  • Alector, Inc. Events
  • Alector, Inc. SEC filings
  • Alector, Inc. Insider transactions
  • Alector, Inc. Transcripts

Frequently asked questions

What does Alector, Inc. (ALEC) do?
Alector, Inc. is a clinical-stage biopharmaceutical company that develops therapies for the treatment of neurodegenerative diseases. Its product candidates include AL001, a humanized recombinant monoclonal antibody in Phase III clinical trials for frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis, and AL101, which is in Phase I clinical trials for neurodegenerative diseases, including Alzheimer's and Parkinson's. The company also offers AL002, a product candidate in Phase II clinical trials for Alzheimer's disease, and AL003, which is in Phase I clinical trials for Alzheimer's disease. Its pipeline includes AL044, which targets MS4A4A, a risk gene for Alzheimer's disease. Alector has a collaboration agreement with Adimab, LLC for antibody research and development, as well as a strategic collaboration with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
Where is ALEC stock listed?
Alector, Inc. trades under the ticker ALEC on NASDAQ.
How can I research ALEC's financials and filings?
Vantafin provides Alector, Inc.'s income statement, balance sheet and cash-flow data, SEC filings, earnings-call transcripts, and insider & institutional ownership on the ALEC profile.